Breaking News, Trials & Filings

AskBio Receives EC Orphan Drug Designation for AB-1003 LGMD Treatment

The drug will evaluate the safety, tolerability and efficacy of a single IV infusion of gene therapy in adult subjects.

Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that the European Commission (EC) has granted orphan drug designation for AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is a novel investigational recombinant adeno-associated virus (AAV) based gene therapy currently being developed as a one-time intravenous (IV) infusion for the treatment of patients with LGMD type 2I/R9 (LGMD2I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters